CATHERINE DEAN: Open Payments
NPI 1780296947 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$895 in 43 payments from 24 companies in 2025. Trend: 2023 $682 · 2024 $941 · 2025 $895
Food & beverage: $895
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 6 | $106 |
| SHIELD THERAPEUTICS INC | 2 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| GENZYME CORPORATION | 4 | $83 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| QOL Medical, LLC | 2 | $65 |
| Novartis Pharmaceuticals Corporation | 2 | $53 |
| Merck Sharp & Dohme LLC | 2 | $45 |
| Janssen Biotech, Inc. | 2 | $32 |
| Incyte Corporation | 1 | $25 |
Products named: ACCRUFER, Sucraid, DUPIXENT, ZENPEP, VOWST, KEYTRUDA, ENTYVIO, TREMFYA.
Industry payments across OK — which companies pay providers there.
